BioTuesdays

Category - Markets

Prothena
Markets

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

December 7, 2020
BiomX
Markets

HCW starts BiomX at buy; PT $20

H.C. Wainwright initiated coverage of BiomX (NYSE American:PHGE) with a “buy” rating and $20 price target. The stock closed at $5.90 on Dec 4. “BiomX is one of the leaders in the development of bacteriophage (phage)...

December 7, 2020
Liquidia Logo
Markets

HCW starts Liquidia Technologies at buy; PT $6

H.C. Wainwright initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and price target of $6. The stock closed at $2.92 on Dec. 3. Liquidia is focused on applying its particle engineering PRINT...

December 4, 2020
Syndax Pharma Logo
Markets

Stifel starts Syndax Pharmaceuticals at buy; PT $32

Stifel launched coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and price target of $32. The stock closed at $22.79 on Dec. 2. Analyst Konstantinos Aprilakis, M.D., writes that SNDX-5613, the...

December 3, 2020
Sutra-Biopharma-Logo
Markets

Stifel starts Sutro Biopharma at buy; PT $25

Stifel initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $25 price target. The stock closed at $16.35 on Dec. 2. Sutro is developing XpressCF, a cell-free protein-synthesis platform that...

December 3, 2020
SQZ-Biotech-Logo
Markets

Analysts start SQZ Biotechnologies at buy

Analysts with Stifel and BTIG launched coverage of SQZ Biotechnologies (NYSE:SQZ) with “buy” ratings and price targets of $38 and $40, respectively. The stock closed at $27.62 on Nov. 23. “We believe SQZ’s Cell Squeeze...

November 24, 2020
Curis Logo
Markets

HCW starts Curis at buy; PT $5

H.C. Wainwright initiated coverage of Curis (NASDAQ:CRIS) with a “buy” rating and price target of $5. The stock closed at $1.35 on Nov. 23. Curis is developing two novel therapeutics for three potential indications that...

November 24, 2020
Biodesix Logo
Markets

Analysts start Biodesix at buy and OP

Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...

November 23, 2020
Silence-Therapeutics-Logo
Markets

BTIG starts Silence Therapeutics at buy; PT $32

BTIG initiated coverage of Silence Therapeutics (NASDAQ, AIM: SLN) with a “buy” rating and $32 price target. The stock closed at $16.70 on Nov. 17. The company is a development stage therapeutics company based on nearly...

November 18, 2020
IMAC-Logo
Markets

AGP starts IMAC Holdings at buy; PT $2.75

Alliance Global Partners launched coverage of IMAC Holdings (NASDAQ:IMAC) with a “buy” rating and price target of $2.75. The stock closed at $1.05 on Nov. 16. IMAC offers regenerative medicine treatments including...

November 17, 2020